

ORIGINAL ARTICLE

Identifying hypoxia in human tumors: A correlation study between ¹⁸F-FMISO PET and the Eppendorf oxygen-sensitive electrodeLISE SAKSØ MORTENSEN^{1*}, SIMON BUUS^{1*}, MARIANNE NORDSMARK¹,
LISE BENTZEN¹, OLE LAJORD MUNK², SUSANNE KEIDING² & JENS OVERGAARD¹¹Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark and
²PET Center, Aarhus University Hospital, Aarhus, Denmark**Abstract**

Introduction. Polarographic oxygen-sensitive electrodes have demonstrated prognostic significance of hypoxia. However, its routine application is limited. ¹⁸F-FMISO PET scans are a noninvasive approach, able to measure spatial and temporal changes in hypoxia. The aim of this study was to examine the association between measures of hypoxia defined by functional imaging and Eppendorf pO₂ electrodes. **Materials and methods.** A total of 18 patients were included, nine squamous cell carcinoma of the head and neck and nine soft tissue tumors. The tumor volume was defined by CT, MRI, ¹⁸FDG-PET or by clinical examination. The oxygenation status of the tumors was assessed using ¹⁸F-FMISO PET imaging followed by Eppendorf pO₂ electrode measurements. Data were compared in a 'virtual voxel', resulting in individual histograms from each tumor. **Results.** The percentages of pO₂ ≤ 5 mmHg ranged from 9 to 94% (median 43%) for all 18 tumors. For ¹⁸F-FMISO PET the T/M ratio ranged from 0.70 to 2.38 (median 1.13). Analyzing the virtual voxel histograms tumors could be categorized in three groups: Well oxygenated tumors with no hypoxia and concordance between the ¹⁸F-FMISO data and the Eppendorf measurements, hypoxic tumors likewise with concordance between the two assays and inconclusive tumors with no concordance between the assays. **Conclusion.** This study analyzed the relationship between ¹⁸F-FMISO PET and Eppendorf pO₂ electrode measurements by use of a virtual voxel model. There was a spectrum of hypoxia among tumors that can be detected by both assays. However no correlation was observed, and in general tumors were more hypoxic based on Eppendorf pO₂ measurements as compared to ¹⁸F-FMISO PET.

Hypoxia persists as a major factor for radiation sensitivity [1–3]. Numerous methods for studying hypoxia in tumors exist. Generally these are based on three different principles. One is the direct measurements of the physical presence of oxygen in tissue such as the Eppendorf pO₂ Histogram. Such principle was the first to demonstrate the prognostic significance of hypoxia in solid tumors [4] followed by other [5–8], but has never been established as a routine clinical assay due to assay related limitations. The method is restricted to accessible tumors only, and cannot differentiate between pO₂ values obtained from necrotic or viable hypoxic cells. The second principle is using markers reduced under hypoxic conditions. These are mainly nitroimidazole compounds that can be detected by e.g. immunohistochemistry or fluorinated radioactive nitroimidazoles

detected by Positron Emission Tomography (PET). Nitroimidazoles enters the cell by passive diffusion and undergo reduction forming reactive species. If oxygen is present the compound is reoxygenated and leaves the cell, but under hypoxic conditions further reduction occurs binding the compound covalently to macromolecules and thereby 'trapping' it inside the cell [9]. This process is dependent on enzymatic activity and thus occurs in viable hypoxic cells only [9–11]. Immunohistochemical analysis requires a tumor biopsy, whereas PET is a non-invasive method that allows repeated measurements of the same tumor and can determine spatial and temporal changes in hypoxia. A range of hypoxia specific PET tracers have been investigated. ¹⁸F-fluoromisonidazole (¹⁸F-FMISO) was the first generation of hypoxia specific PET tracers and so far the most widely used

*Shared first authorship.

Correspondence: Lise Saksø Mortensen, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44 Bldg. 5, 2nd Floor, DK-8000 Aarhus C, Denmark. Tel: +45 89492639. E-mail: lsm@oncology.dk

(Received 11 June 2010; accepted 13 August 2010)

[12,13]. Results obtained by ^{18}F -FMISO PET have shown that the degree of hypoxia varies within individual tumors and between tumors of identical histology [14]. Recently the use of other specific tracers has been applied, e.g. ^{18}F -FAZA, ^{18}F -EF5, Cu-ATSM [9]. The third principle for measuring hypoxia is by studying endogenous markers (such as HIF-1 α , CAIX), or genes regulated by hypoxia [15].

In the current study hypoxia measured by ^{18}F -FMISO PET was compared with oxygenation status obtained by the polarographic needle electrodes within the same tumor. A few clinical studies have performed such comparison, with mixed results. The aim of this study was to examine the association between measures of hypoxia defined by functional imaging and Eppendorf pO_2 electrodes.

Materials and methods

Patients

A total of 18 patients with pretreatment tumor pO_2 measurements and tumor hypoxia assessment using ^{18}F -FMISO scans were included in the study. Prior to entering written informed consent was obtained from all patients and the study was approved by the Ethics Committee of Aarhus County, Denmark. Nine patients had biopsy proven squamous cell carcinoma of the head and neck (HNSCC). Five patients had soft tissue sarcomas and four had benign soft tissue tumors. Eight of these patients have previously been published [16].

Tumor volume was defined by CT, MRI, ^{18}F FDG-PET or by clinical examination. In patients with HNSCC measurements were made in a single lymph node, in patients with soft tissue tumors the primary tumor was measured. In the following the term "tumor" will refer to the region studied regardless of that being primary tumor or lymph node. Measurements of hypoxia by ^{18}F -FMISO PET and Eppendorf were in general made in the same site (either primary tumor or a lymph node). The ^{18}F -FMISO scan was in general followed by pO_2 measurements within the same day, $n=13$. However, in four patients the pO_2 measurements were performed 6–14 days after an ^{18}F -FMISO scan and in one case tumor pO_2 measurements was followed by ^{18}F -FMISO PET the day after.

Eppendorf

The partial oxygen pressure (pO_2) of the tumors was measured by a 0.35 mm diameter computerized polarographic needle electrode (Eppendorf, Germany). Further details are described elsewhere [17]. In short, the computerized oxygen electrode was inserted into the tumor under visual guidance and multiple measures of pO_2 were obtained as the probe moved automatically

along a measurement track. The distance between each pO_2 value was 0.7 mm, and represents the average pO_2 of a sampling range that covers several cell layers irrespective of cell origin (malignant or normal) and viable status. The length and number of tracks depended on tumor size and accessibility. In order to minimize intra-tumor variability a minimum of three electrode tracks were obtained per tumor. Tumor oxygenation status was reported as the fraction of pO_2 measurements ≤ 5 mmHg.

^{18}F -FMISO PET

^{18}F -FMISO was synthesized as previously described [18]. The PET scans were performed using a Siemens ECAT EXACT HR 47 scanner. Patients were intravenously injected by 400 MBq ^{18}F -FMISO (median 394, range 218–462 MBq) and a static scan was performed 150–249 minutes later (median 211 minutes). The HNSCC patient wholebody scans were reconstructed with the OSEM method (16 subsets and 6 iterations) and a 10 mm gaussian filter. The resulting images contained $128 \times 128 \times 92$ voxels with a size of $4.4 \times 4.4 \times 4.4$ mm³. The scans of the patients with soft tissue sarcomas and benign soft tissue tumors each consisted of a single bedposition and were reconstructed using the same algorithm and resampled to the same voxel size ($4.4 \times 4.4 \times 4.4$ mm³). For reference additional ROIs were drawn in muscle tissue. Data was reported as ratios of tumor to muscle radioactivity (T/M ratio).

Data analysis

The virtual voxel was generated to allow a direct comparison of voxel based distributions of hypoxia in a tumor measured by ^{18}F -FMISO PET and Eppendorf pO_2 electrodes respectively, Figure 1A–F. In order to perform this comparison the Eppendorf pO_2 measurements were converted to an "Eppendorf virtual voxel". Since the voxel size of the ^{18}F -FMISO PET scan in this study was $4.4 \times 4.4 \times 4.4$ mm³, the Eppendorf pO_2 measurements of seven successive pO_2 values (7×0.7 mm = 4.9 mm³) were aligned to represent one dimension of an ^{18}F -FMISO voxel. The alignment of the pO_2 measurements were done consecutively i.e. the first "Eppendorf virtual voxel" consisted of seven pO_2 measurements number 1 to 7, the next of numbers 2 to 8 etc. This approach was used in order to simulate This approach was used in order to simulate the partial volume effect inherent in PET data, where the signals in neighboring voxels are correlated. After grouping the pO_2 values in "Eppendorf virtual voxels", the amount of hypoxia in each voxel was determined. In this study Eppendorf pO_2 values ≤ 5 mmHg were defined as

being hypoxic. Thus, for each tumor the percentage of pO_2 values ≤ 5 mmHg was determined for each "Eppendorf virtual voxel" (e.g. if 3/7 pO_2 values were ≤ 5 mmHg = 42% hypoxia in the "Eppendorf virtual voxel", if 1/7 pO_2 value ≤ 5 mmHg = 14% hypoxia). For each tumor the distribution of "Eppendorf virtual voxel hypoxic fraction" are presented in a histogram (Figure 1B and C).

For each tumor the ^{18}F -FMISO T/M ratio in each individual voxel was calculated; voxel values ≤ 1 were defined as non hypoxic (assuming muscle tissue is non hypoxic) whereas voxel values ≥ 3.7 was defined as being hypoxic. The percentage of hypoxia was calculated within each voxel by dividing the actual T/M value with 3.7 (Figure 1D and E). For each patient median hypoxia based on the above analysis was determined for ^{18}F -FMISO and Eppendorf pO_2 measurements, respectively.

Results

Patient and tumor characteristics are shown in Table I. Tumor size varied considerably with a range of 6 to 2593 ml (median 55 ml). No correlation was observed between tumor volume and hypoxia determined by the physiological pO_2 or by ^{18}F -FMISO PET. Eppendorf pO_2 showed that the percentages of $pO_2 \leq 5$ mmHg ranged from 9 to 94% (median 43%) for all 18 tumors. The median number of tracks was 6 (range 4–10) and the number of pO_2 values ranged from 56 to 230 (median 108). The range of percentages of

pO_2 values ≤ 5 mmHg for the nine HNSCC, the five soft tissue sarcomas and the four benign tumors, were 13–94% (median 48%), 19–68% (median 44%) and 9–39% (median 31%), respectively.

The ^{18}F -FMISO T/M ratio among all tumors ranged from 0.70 to 2.38 (median 1.13). The nine HNSCC had an ^{18}F -FMISO T/M ratio range of 1.18–2.38 (median 1.68). The five sarcomas had an ^{18}F -FMISO T/M ratio range of 0.70–1.00 (median 0.78). For the four benign soft tissue tumors the ^{18}F -FMISO T/M ratio range was 0.77–1.05 (median 0.93).

In general tumors were classified as more hypoxic based on Eppendorf pO_2 measurements as compared with ^{18}F FMISO PET. The Eppendorf pO_2 measurements showed a large variation in the amount of hypoxia within the tumors. Overall HNSCC and soft tissue sarcomas were more hypoxic than the benign tumors. The ^{18}F -FMISO T/M ratios indicated that the HNSCC were hypoxic, whereas the benign soft tissue tumors were non hypoxic by ^{18}F -FMISO PET, with a T/M ratio close to one. Unexpectedly, the T/M ratio was also close to one in the soft tissue sarcomas.

Results from all tumors were presented in Figure 3 as the virtual voxel median hypoxia measured by Eppendorf and ^{18}F -FMISO PET, respectively. No statistical significant correlation could be demonstrated. From data presented in Figure 3 tumors were categorized in three groups: Concordance between the ^{18}F -FMISO data and the Eppendorf measurements showing a well oxygenated tumor (Figure 2A),

Table I. Patient and tumor characteristics.

Patient number	Histology	Tumor volume (ml)	No. of pO_2 measurements	No. of Eppendorf tracks	HF5 (%)	^{18}F -FMISO T/M (median)	Eppendorf virtual voxel median hypoxia (%)	^{18}F -FMISO virtual voxel median hypoxia (%)
1	Benign	14 ^a	56	4	9	1.05	0	0
2	Benign	59 ^b	230	8	37	0.88	14	0
3	Benign	54 ^b	93	7	39	0.99	43	0
4	Benign	477 ^b	123	6	24	0.77	0	0
5	HNSCC	107 ^c	183	10	74	1.87	100	29
6	HNSCC	80 ^a	213	6	13	2.38	0	57
7	HNSCC	30 ^a	56	6	48	1.68	43	29
8	HNSCC	6 ^b	86	5	47	1.19	64	0
9	HNSCC	7 ^a	67	5	31	1.30	14	14
10	HNSCC	25 ^a	105	6	55	1.94	57	29
11	HNSCC	7 ^a	81	6	94	1.14	100	0
12	HNSCC	56 ^a	112	4	69	2.21	71	43
13	HNSCC	15 ^b	70	5	43	1.12	43	0
14	Sarcoma	303 ^a	192	6	42	0.79	29	0
15	Sarcoma	2593 ^a	179	9	68	0.70	86	0
16	Sarcoma	20 ^b	131	7	19	0.97	0	0
17	Sarcoma	727 ^b	192	7	68	0.71	79	0
28	Sarcoma	105 ^b	83	7	20	1.40	0	14

^aVolume defined by MR/ ^{18}F -FMISO PET.

^bVolume defined by clinical examination/ ^{18}F -FMISO PET.

^cVolume defined by ^{18}F FDG PET/ ^{18}F -FMISO PET.




Figure 2. Three examples of ¹⁸F-FMISO tumor imaging and the corresponding virtual voxel histograms. A: Patient number 1 with concordance between Eppendorf pO₂ measurements and ¹⁸F-FMISO PET (both showing little/no hypoxia). B: Patient number 12 likewise with concordance between Eppendorf pO₂ measurements and ¹⁸F-FMISO PET (both showing hypoxia). C: Patient number 15 with lack of concordance between Eppendorf pO₂ measurements (showing high degree of hypoxia) and ¹⁸F-FMISO PET (showing very little hypoxia).

a hypoxic tumor (Figure 2B) and a tumor with no concordance between the assays (Figure 2C). In the category with no concordance between the assays, generally the ¹⁸F-FMISO uptake was low (close to 0% hypoxia within the virtual voxel), whereas the low

pO₂ measured by Eppendorf was in disagreement to this (some measurements within the virtual voxel showing 100% hypoxia). In this group all three tumor types (HNSCC, benign tumors and sarcomas) were represented.




Figure 3. Comparison between the virtual voxel median hypoxia measured by Eppendorf pO_2 electrodes and ^{18}F -FMISO PET, respectively. The dotted line indicates an ideal situation with total concordance between the two different assays. Red symbol: HNSCC. Blue symbol: Benign tumors. Green symbol: Soft tissue tumors. A, B, C refers to tumor categories as exemplified in figure 2.

Discussion

The present study correlated measurements of physiological pO_2 and ^{18}F -FMISO PET. Only few clinical studies have done similar comparison and all studies have very few patients. Bentzen et al. reported of 13 patients with soft tissue tumors (of which some also participates in this study) [16] and showed no correlation. In contrast Gagel et al. reported a significant correlation between ^{18}F -FMISO T/M and the fraction of $pO_2 \leq 2.5$, 5 and 10 mmHg, respectively in two studies of 16 and 22 head and neck cancer patients [19,20].

In accordance with the current study a comparison between the nitroimidazole, pimonidazole and Eppendorf pO_2 in uterine cervical cancer showed no correlation [21]. This study indicated a higher degree of hypoxia by the Eppendorf pO_2 measurements as compared with pimonidazole.

There are several possible explanations for the disagreement between results obtained by the two assays. The ^{18}F -FMISO PET scan has inherent limitations; the low resolution of the clinical PET scanner; signal from a single voxel represents a large heterogeneous tissue area. In a preclinical study by Busk et al. [22] xenografts injected with fluoroazomycin arabinoside (^{18}F -FAZA, a similar PET hypoxia-tracer), reported that some PET pixels were classified as non-hypoxic, yet autoradiography exposed foci of hypoxic cells. These pixels would be classified correctly if the resolution was improved from 4 to 2 mm, which is the resolution of an animal micro-PET scanner [23]. Other limitations for ^{18}F -FMISO PET are the slow

washout of unbound tracer from the background, the partial volume effect applying for small tumors, the ^{18}F -FMISO data being a result of a 2–3 hour period (from ^{18}F -FMISO injection to PET scan) resulting in primarily visualization of chronic hypoxia. Defining the tumor volume may be a source of uncertainty which unfortunately hampered the present study due to lack of proper co-registration. Improved co-registration is presumably of major importance to obtain a strong correlation as emphasized by a recent preclinical study by Chang et al. [24]. They showed that ^{18}F -FMISO PET image intensity correlated with OxyLite-measured pO_2 when using a robotic system that allows 3D tracking of the electrode tip.

The Eppendorf pO_2 electrodes have other characteristics; pO_2 is measured instantly thereby reflecting both acute and chronic hypoxia. The necrotic areas of the tumors are identified as being hypoxic which may explain why some of the sarcomas in the current study are more hypoxic measured by Eppendorf electrodes, and have no uptake of ^{18}F -FMISO. Furthermore, the Eppendorf pO_2 measurement needle track may not be representative for the entire tumor volume.

Several assumptions applied to the “virtual voxel”-model. For the Eppendorf measurements values above 5 mmHg were defined as non hypoxic, while measurements below or equal to 5 mmHg were considered to be hypoxic. This is in agreement with *in vitro* studies on the ^{18}F -FMISO hypoxic binding capacity [11]. Furthermore, this value is in agreement with the level of radiobiological hypoxia [25,26]. The ^{18}F -FMISO value of T/M ratio ≥ 3.7 for total hypoxia was chosen empirically as the second highest individual value of ^{18}F -FMISO T/M ratio measured in the current study. This value is somewhat higher than what have been used in other studies [12,14,27], but was found to be most representative for extreme hypoxia.

In conclusion this study analyzed the relationship between ^{18}F -FMISO PET and Eppendorf pO_2 electrode measurements by use of a virtual voxel model. There was a spectrum of hypoxia among tumors that can be detected by both assays. However no correlation was observed, and in general tumors were more hypoxic based on Eppendorf pO_2 measurements as compared to ^{18}F -FMISO PET.

Acknowledgements

Supported by the Danish Cancer Society, CIRRO – The Lundbeck Foundation Center for Interventional Research in Radiation Oncology and The Danish Council for Strategic Research.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

- [1] Overgaard J. Sensitization of hypoxic tumour cells – clinical experience. *Int J Radiat Biol* 1989;56:801–11.
- [2] Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. *Semin Radiat Oncol* 1996;6:10–21.
- [3] Overgaard J. Hypoxic radiosensitization: Adored and ignored. *J Clin Oncol* 2007;25:4066–74.
- [4] Kolstad P. Inter-capillary distance, oxygen tension and local recurrence in cervix cancer. *Scand J Clin Lab Invest Suppl* 1968;106:145–57.
- [5] Hockel M, Vordran B, Schlenger K, Bausmann E, Knapstein PG. Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. *Gynecol Oncol* 1993;51:141–9.
- [6] Nordmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. *Radiother Oncol* 1996;41:31–9.
- [7] Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. *Radiother Oncol* 1998;48:149–56.
- [8] Nordmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiother Oncol* 2005;77:18–24.
- [9] Lapi SE, Voller TF, Welch MJ. Positron emission tomography imaging of hypoxia. *PET Clin* 2009;4:39–47.
- [10] Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. *Radiol Clin North Am* 2005;43:169–87.
- [11] Franko AJ, Koch CJ, Garrecht BM, Sharplin J, Hughes D. Oxygen dependence of binding of misonidazole to rodent and human tumors *in vitro*. *Cancer Res* 1987;47:5367–76.
- [12] Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. *Int J Radiat Oncol Biol Phys* 1992;22:199–212.
- [13] Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18]fluoromisonidazole positron emission tomography in head and neck cancer. *Clin Cancer Res* 2006;12:5435–41.
- [14] Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. *Int J Radiat Oncol Biol Phys* 1996;36:417–28.
- [15] Sorensen BS, Toustrup K, Horsman MR, Overgaard J, Alsner J. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas *in vitro*. *Acta Oncol* 2010;49:895–905.
- [16] Bentzen L, Keiding S, Nordmark M, Falborg L, Hansen SB, Keller J, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. *Radiother Oncol* 2003;67:339–44.
- [17] Nordmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. *Acta Oncol* 1994;33:383–9.
- [18] Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography—a study evaluating [18F]Fluoro-2-deoxy-D-glucose. *Acta Oncol* 2000;39:629–37.
- [19] Gagel B, Reinartz P, DiMartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO(2) Polarography versus positron emission tomography ([18F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. *Strahlenther Onkol* 2004;180:616–22.
- [20] Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: Validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? *BMC Cancer* 2007;7:113.
- [21] Nordmark M, Loncaster J, Aquino-Parsons C, Chou SC, Gebiski V, West C, et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. *Radiother Oncol* 2006;80:123–31.
- [22] Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: Voxel size matters. *Acta Oncol* 2008;47:1201–10.
- [23] Busk M, Horsman MR, Jakobsen S, Hansen KV, Bussink J, van der Kogel A, et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? *Radiother Oncol* 2009;92:429–36.
- [24] Chang J, Wen B, Kazanzides P, Zanzonico P, Finn RD, Fichtinger G, et al. A robotic system for 18F-FMISO PET-guided intratumoral pO2 measurements. *Med Phys* 2009;36:5301–9.
- [25] Horsman MR, Khalil AA, Nordmark M, Grau C, Overgaard J. Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. *Radiother Oncol* 1993;28:69–71.
- [26] Horsman MR, Khalil AA, Siemann DW, Grau C, Hill SA, Lynch EM, et al. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. *Int J Radiat Oncol Biol Phys* 1994;29:439–42.
- [27] Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. *Eur J Nucl Med Mol Imaging* 2003;30:695–704.